Amy­lyx wel­comes for­mer Al­ny­lam ex­ec to help ex­pand Re­lyvrio; Amarin plugs in an in­ter­im chief

Masako Naka­mu­ra will lead Re­lyvrio’s march to key re­gions as Amy­lyx’s gen­er­al man­ag­er and head of the Asia Pa­cif­ic and Latin Amer­i­ca in­ter­na­tion­al mar­kets. Naka­mu­ra, the SVP, head of Asia at Al­ny­lam from 2018-21, tack­led a sim­i­lar gig as GM, Asia with Aege­ri­on Phar­ma­ceu­ti­cals and had a 10-year ca­reer at Gen­zyme. Cana­da ap­proved Amy­lyx’s ALS drug, known in that coun­try as Al­bri­oza, in June 2022, while the FDA gave it the go-ahead in Sep­tem­ber fol­low­ing an un­con­ven­tion­al sec­ond ad­comm.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.